Background. Islet allograft rejection in sensitized recipients is difficult to control by costimulation blockade using anti-CD154 and cytotoxic T-lymphocyte antigen-4 immunoglobulin (CTLA4Ig). Because leukocyte function antigen (LFA) 1 is highly expressed on memory T cells, adding an LFA-1 blockade may inhibit memory T-cell activities. We examined the effects on islet allograft survival of triple costimulation blockade in presensitized recipient mice. Methods. C57BL/6 mice were sensitized by transplantation under the kidney capsule or intraperitoneal injection of Balb/c islets. Four weeks after transplantation, sensitization was confirmed by flow-cytometric detection of alloreactive antibodies. Diabetes was induced by a single intravenous i...
OBJECTIVE: The first Phase I study of autologous tolerogenic dendritic cells (Tol-DCs) in Type 1 dia...
International audienceAIM: This study describes the ability of intravenous donor apoptotic leukocyte...
<p>B6 mice were treated with MHC I + IL-2/anti-IL-2 and subsequent MHC II + IL-2 prior to transplant...
Clinical islet transplantation is a successful procedure that can improve the quality of life in rec...
P>Memory T cells are known to play a key role in prevention of allograft tolerance in alloantigen-pr...
BACKGROUND: Donor-specific transfusion (DST) and a brief course of anti-CD154 monoclonal antibody (m...
OBJECTIVE: Costimulation blockade has emerged as a selective nontoxic maintenance therapy in transpl...
Costimulation blockade is a promising strategy for preventing allograft rejection and inducing toler...
The rate of success in clinical transplantation of islets of Langerhans has dramatically improved wi...
Treatment of mice with a single donor-specific transfusion (DST) plus a brief course of anti-CD154 m...
Pancreatic islet transplantation is a promising treatment modality for patients with insulin- depend...
BACKGROUND: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve s...
Anti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet trans...
Costimulation blockade is a promising strategy for pre-venting allograft rejection and inducing tole...
BACKGROUND: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve s...
OBJECTIVE: The first Phase I study of autologous tolerogenic dendritic cells (Tol-DCs) in Type 1 dia...
International audienceAIM: This study describes the ability of intravenous donor apoptotic leukocyte...
<p>B6 mice were treated with MHC I + IL-2/anti-IL-2 and subsequent MHC II + IL-2 prior to transplant...
Clinical islet transplantation is a successful procedure that can improve the quality of life in rec...
P>Memory T cells are known to play a key role in prevention of allograft tolerance in alloantigen-pr...
BACKGROUND: Donor-specific transfusion (DST) and a brief course of anti-CD154 monoclonal antibody (m...
OBJECTIVE: Costimulation blockade has emerged as a selective nontoxic maintenance therapy in transpl...
Costimulation blockade is a promising strategy for preventing allograft rejection and inducing toler...
The rate of success in clinical transplantation of islets of Langerhans has dramatically improved wi...
Treatment of mice with a single donor-specific transfusion (DST) plus a brief course of anti-CD154 m...
Pancreatic islet transplantation is a promising treatment modality for patients with insulin- depend...
BACKGROUND: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve s...
Anti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet trans...
Costimulation blockade is a promising strategy for pre-venting allograft rejection and inducing tole...
BACKGROUND: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve s...
OBJECTIVE: The first Phase I study of autologous tolerogenic dendritic cells (Tol-DCs) in Type 1 dia...
International audienceAIM: This study describes the ability of intravenous donor apoptotic leukocyte...
<p>B6 mice were treated with MHC I + IL-2/anti-IL-2 and subsequent MHC II + IL-2 prior to transplant...